China - PhaseZero Market Insight Report
Whythawk, July 2010, Pages: 25
Whythawk PhaseZero reports offer rapid, high-level comparative country insight. Our reports combine quantitative and qualitative content with striking data visualisation. To assist comprehension, chart elements - called sparklines - are integrated throughout the report to allow concise and immediate comparisons of all reported data.
Charts and data are presented relative to a benchmark of leading emerging market investment destinations. All content is comprehensively referenced with online links embedded into the report for immediate access to source documentation.
China has been analysed according to the following segments:
1. Demography: Population, Health and Education
2. Economy: Market Opportunity and Investment Environment
3. Infrastructure: Telecommunications, Energy, Access and Rights
4. State: Governance, Law and Stability
5. Structure: Aid, Enterprise and State Expenditure
6. Healthcare: Morbidity, Mortality & Treatment
A flavour of major economic opportunities and risks highlighted in the PhaseZero China report:
- China's government has opened a new range of government-run industries to the private sector, either through investment in existing companies or establishment of new firms. The government also announced Thursday that it would improve financing services and simplify administrative procedures for private sector involvement in those industries.
- China National Nuclear Corp. set up a venture with local partners in Fujian province to build fourth-generation reactors. China is developing nuclear energy to help cut reliance on more polluting coal and oil and to meet surging electricity demand.
- China's offshore direct investment more than doubled to a record $56.0 billion in 2008. Its companies now own international assets worth $184.0 billion and the country's leaders are keen to acquire more in 2010. State-owned enterprises accounted for 85.4 percent of the total, compared with 0.3 percent by private enterprises, China's commerce ministry said. It did not account for the rest.
- In November 2009, Swiss pharmaceutical giant, Norvatis, announced plans to invest $1.25 billion in two Chinese Research & Development (R&D) centres over five years. Novartis will put $250.0 million into a new R&D centre and manufacturing facility in Changshu, a city near Shanghai, and another $1.0 billion to add 1,000 researchers at an existing centre in Shanghai. This is an effort to tap into one of the fastest growing healthcare markets."
China Market Insight Contents
Country Overview
Introduction to China
The Bue Curve and Emerging Market Analysis
Methodology: Bue Analysis
Bue Analysis
Comparative GDP Forecast, and Exchange Rate Base Year and Value
Segment 1: Demography
Segment 2: Economy
Segment 3: Infrastructure
Segment 4: State
Segment 5: Structure
Segment 6: Healthcare
Bue Analysis Conclusions
References: Data Sources
References: Content Sources
China Market Insight Figures
Key Country Rankings (China), 2010
Bue Curve - Summary of Results (China), 2010
Gross domestic product, current prices in US dollars (China), 2010
Yuan Renminbi Vs. US Dollar, 2000 - 2009
Key Population and Education Indicators (China), 2010
Key Health Indicators (China), 2010
Key Market Opportunity Indicators (China), 2010
Key Investment Environment Indicators (China), 2010
Key Telecommunications Indicators (China), 2010
Key Energy Indicators (China), 2010
Key Governance and Legal Indicators (China), 2010
Key Stability Indicators (China), 2010
Key State Ease of Business Indicators (China), 2010
Key Aid and Enterprise Indicators (China), 2010
Key Mortality and Morbidity Indicators (China), 2010
Key Treatment Indicators (China), 2010
Final Table of Bue Scores (China), 2010
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
